Latest News

07.22.21

908 Devices and Transcenta’s Joint Innovation Partnership Accelerates Biopharma Development

908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced outcomes of its joint innovation partnership with Transcenta, a global biotherapeutics company. Transcenta has implemented 908 Devices’ technologies within its Process...

Read More

908 Devices Announces New Data Integrations with Key Industry Partners to Accelerate BioProcess Data Insights

06.22.21

908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer, Labcorp Diagnostics, to its Board of Directors

06.08.21

908 Devices Increases Focus on Biotherapeutics with Expansion of Scientific Advisory Board

05.07.21

908 Devices and Bio-Techne Announce Joint Collaboration

05.04.21

908 Devices Appoints Michele Fournier as Chief People Officer

04.13.21

908 Devices Strengthens Commercial Team with Addition of New Vice President

02.09.21

908 Devices Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

12.23.20

908 Devices Announces Pricing of Initial Public Offering

12.18.20

908 Devices Names Kevin Hrusovsky, 30-year Biotechnology Veteran and Founder of Powering Precision Health, as Chairman of its Board of Directors

10.31.20

908 Devices Announces New Additions to Its Executive Team

10.15.20

SCIEX and 908 Devices Launch Solutions for the Characterization of Biotherapeutics

08.04.20